JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

Home・Lista de Ações・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Fechado

SetorSaúde

65.56 -1.62

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

65.27

Máximo

67.29

Indicadores-chave
By Trading Economics
Rendimento	155M -24M
Vendas	229M 256M
Margem de lucro	-9.26
Funcionários	711
EBITDA	-546M -148M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+22.55% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de fev. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	3.2B 9.3B
Abertura anterior	67.18
Fecho anterior	65.56

Sentimento de Notícias

By Acuity

27%

73%

51 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

11.5 / 12.23 Suporte e Resistência

Arrowhead Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de jan. de 2026, 23:51 UTC

Ganhos

Correction to Samsung Fourth-Quarter Net Profit Article

28 de jan. de 2026, 23:49 UTC

Ações em Alta

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 de jan. de 2026, 23:19 UTC

Ganhos

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 de jan. de 2026, 22:43 UTC

Ganhos

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 de jan. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 de jan. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 de jan. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 de jan. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 de jan. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 de jan. de 2026, 23:30 UTC

Conversa de Mercado

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 de jan. de 2026, 23:28 UTC

Ganhos

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 de jan. de 2026, 23:26 UTC

Ganhos

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 de jan. de 2026, 23:21 UTC

Ganhos

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 de jan. de 2026, 23:18 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 de jan. de 2026, 22:58 UTC

Ganhos

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 de jan. de 2026, 22:48 UTC

Conversa de Mercado

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 de jan. de 2026, 22:45 UTC

Ganhos

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 de jan. de 2026, 22:44 UTC

Ganhos

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 de jan. de 2026, 22:43 UTC

Ganhos

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 de jan. de 2026, 22:41 UTC

Ganhos

Ações em Alta

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 de jan. de 2026, 22:41 UTC

Conversa de Mercado

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 de jan. de 2026, 22:41 UTC

Ganhos

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 de jan. de 2026, 22:40 UTC

Ganhos

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 de jan. de 2026, 22:39 UTC

Ganhos

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 de jan. de 2026, 22:38 UTC

Ganhos

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 de jan. de 2026, 22:37 UTC

Ganhos

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 de jan. de 2026, 22:35 UTC

Ganhos

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 de jan. de 2026, 22:26 UTC

Conversa de Mercado

Ganhos

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 de jan. de 2026, 22:20 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

28 de jan. de 2026, 22:20 UTC

Conversa de Mercado

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Comparação entre Pares

Variação de preço

Arrowhead Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

22.55% parte superior

Previsão para 12 meses

Média 82 USD 22.55%

Máximo 110 USD

Mínimo 35 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Arrowhead Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Arrowhead Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

11.5 / 12.23Suporte e Resistência

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentimento

By Acuity

51 / 352 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.